All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Live Symposium

How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma

At the ESH 7th Translational Research Conference:

Multiple Myeloma

with Martin Kaiser, Mohamad Mohty, and Rakesh Popat

Saturday, October 5, 2024 | 09:10-10:10 CEST

Register now

This independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-05-07T09:45:21.000Z

Dual antigen targeting immunotherapies in MM

May 7, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Immune-based therapies in multiple myeloma (MM) include agents such as chimeric antigen receptor (CAR) T cells, as well as bispecific antibody therapies. These novel agents are often associated with high initial response rates compared with standard therapies, yet most patients go on to experience a relapse. In an effort to improve duration of response, dual antigen targeting and trispecific antibodies are currently being investigated in MM.1

Here we summarize a presentation by Sham Mailankody1 from the International Myeloma Society’s 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop, 2024, on antigen-targeting CAR T cells and antibody therapies in MM.

Dual antigen-targeting1

  • The high incidence of relapse after immune therapies can be attributed to a multitude of resistance mechanisms; most commonly reduction or loss of the target antigen.
  • Immune therapies such as CAR T cells and bispecific antibodies are often administered sequentially after relapse. However, use of these therapies in combination to target more than one antigen simultaneously could be applied to further reduce malignant cells and extend duration of response.
  • In a mouse model, dual targeting of B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D) resulted in a more durable response than either monotherapy in isolation.
  • Dual antigen targeting can be achieved using combinations of CAR T-cell and bispecific antibody therapies (Figure 1).

Figure 1. Methods of dual antigen-targeting in MM* 

CAR, chimeric antigen receptor; TCE, T-cell engager.
Created with BioRender.com.
*Adapted from Mailankody.1

RedirecTT-11

  • RedirecTT-1 (NCT04586426) is a phase I/II clinical trial investigating the combination of teclistamab and talquetamab to simultaneously target BCMA and GPRC5D for the treatment of relapsed/refractory MM.
    • The trial design and latest data from RedirecTT-1 have been reported by the Multiple Myeloma Hub here.
  • Data collected from this trial provide evidence to support dual antigen targeting as a strategy to aid improve response rates, particularly in difficult-to-treat presentations such as extramedullary disease (EMD) (Figure 2).

Figure 2. Response rates from RedirecTT-1 in A response-evaluable patients and B patients with EMD* 

CR, complete response; PR, partial response; Q2W, once every 2 weeks; sCR, stringent complete response; tal, talquetamab; tec, teclistamab; VGPR, very good partial response.
*Adapted from Mailankody.1

Key learnings1

  • Preclinical data and early clinical trials suggest that dual antigen targeting could help to overcome resistance mechanisms to immune therapies.
  • More research is required in the clinical setting to establish whether dual antigen targeting results in increased response rates and, most importantly, increased response duration.

  1. Mailankody S. Dual antigen-targeted CAR T cells and trispecific antibodies. 2024 International Myeloma Society 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop. Mar 23, 2024; Boston, US.

Your opinion matters

HCPs, what is your preferred format for educational content on the Multiple Myeloma Hub?
39 votes - 30 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox